Targeting the mTOR signaling pathway in neuroendocrine tumors

Current treatment options in oncology

Volumn 15, Issue 3, 2014, Pages 365-379

  Chan, Jennifer ^a   Kulke, Matthew ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMORS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 85027953660     PISSN: None     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0294-4     Document Type: Review

References (0)